Metal complexes have been used as pharmaceuticals and medicine throughout the world, showing antimicrobial, antitumor and anti-arthritis. The medicinal use of metals has a long history, existing for more than 5000 years in China. With the discovery of the activity antineoplastic cisplatin by Rosenberg in 1970, the study of these complexes and their application intensified due to the success in their implementation, encouraging the development of other complexes with antitumor activity in in vitro tests, involving substances such as gallium, germanium, tin, bismuth, titanium, ruthenium, rhodium, iridium, molybdenum, copper, silver, palladium and gold. Metal complexes based palladium use are being considered as having antibacterial activity and as an alternative for the treatment of cancer due to the similarity of chemical coordination which possess in platinum ratio, an example being cytotoxic activity against acute lymphoblastic leukemia T cells ( MOLT-4) demonstrated in vitro, for complexes of platinum and palladium with tyrosine, alanine and methionine. The use of silver compounds as antimicrobial agents began with the use of silver nitrate in middle age to cure skin infections. In recent years, new antimicrobial agents based on the use of silver were synthesized and studied in order to obtain new more efficient compounds against pathogenic micro-organisms. It has been as an example the inhibitory activity against Gram-positive and Gram-negative silver complex by histidine, tryptophan and acesulfame, overcoming bacterial resistance due to several mechanisms of action have. The misuse and the extremely widespread use of these silver complexes are generating some resistant bacterial colonies, leading to the great interest in the development of new compounds. According to these reports, this research project aims at the synthesis, characterization and realization of pharmacological tests in vitro of new complexes of silver and palladium with indapamide bioactive ligands and chlorthalidone and performing growth inhibition tests mobile and mutagenicity.
News published in Agência FAPESP Newsletter about the scholarship: